产品
编 号：F750300
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2243227-60-1
产品详情
生物活性：
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
体内研究：
KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model.KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice.Animal Model:SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg; every other day; 21 d
Result:Led to strong inhibition of tumor growth when combined with Rituximab.
体外研究：
KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage.KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines.
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
体内研究：
KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model.KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice.Animal Model:SIRPA knock-in mouse model injected with Burkitt’s lymphoma cells
Dosage:10 mg/kg
Administration:Intraperitoneal injection; 10 mg/kg; every other day; 21 d
Result:Led to strong inhibition of tumor growth when combined with Rituximab.
体外研究：
KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage.KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备